Goldman Sachs downgraded WuXi Biologics to Neutral from Buy with a price target of HK$21.60, down from HK$50. The firm notes the China CRO/CDMO sector has experienced significant market volatility following the introduction of a draft version of the “BIOSECURE Act” bill in the U.S. House of Representatives on January 25 – and a subsequent, similar bill proposed in the U.S. Senate last week.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on WXIBF: